Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program "Treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
Postepy Dermatol Alergol
; 39(4): 723-728, 2022 Aug.
Article
en En
| MEDLINE
| ID: mdl-36090728
Texto completo:
1
Bases de datos:
MEDLINE
Tipo de estudio:
Evaluation_studies
Idioma:
En
Revista:
Postepy Dermatol Alergol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Polonia